Target Validation Information
Target ID T52921
Target Name Nociceptin receptor
Target Type
Clinical Trial
Drug Potency against Target 1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol Drug Info Ki = 4 nM [528785]
1-benzhydryl-4-(furan-2-yl)piperidin-4-ol Drug Info Ki = 136 nM [528781]
1-benzhydryl-4-hexylpiperidin-4-ol Drug Info Ki = 1147 nM [528781]
1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol Drug Info Ki = 1667 nM [528781]
MeBut-RYYRIK-NH2 Drug Info IC50 = 21.3 nM [529208]
Piv-RYYRIK-NH2 Drug Info IC50 = 14.9 nM [529208]
Hex-RYYRIK-NH2 Drug Info IC50 = 21.7 nM [529208]
FGGFTGARKSARK Drug Info IC50 = 0.353 nM [526185]
Ada-RYYRIK-NH2 Drug Info IC50 = 3.42 nM [529208]
FGGFTGARKSARKL Drug Info IC50 = 0.52 nM [526185]
IsoVa-RYYRIK-NH2 Drug Info IC50 = 7.42 nM [529208]
FGGFTGARKCARKC Drug Info IC50 = 0.471 nM [526185]
For-RYYRIK-NH2 Drug Info IC50 = 0.66 nM [529208]
Va-RYYRIK-NH2 Drug Info IC50 = 5.67 nM [529208]
FGGFTGCRKSCRK Drug Info IC50 = 3.04 nM [526185]
Bu-RYYRIK-NH2 Drug Info IC50 = 1.86 nM [529208]
2,2-diMeBut-RYYRIK-NH2 Drug Info IC50 = 45.5 nM [529208]
2-MePen-RYYRIK-NH2 Drug Info IC50 = 47.3 nM [529208]
T-BuAc-RYYRIK-NH2 Drug Info IC50 = 16.9 nM [529208]
FGGFTGARKSARKKKNQ Drug Info IC50 = 0.16 nM [529719]
FGGFTGARKSARKVANQ Drug Info IC50 = 1.1 nM [529719]
FGGFTGARKSARKLLNQ Drug Info IC50 = 0.48 nM [529719]
FGGFTCARKCARK Drug Info IC50 = 3.03 nM [526185]
FGGFTGARKSARKWANQ Drug Info IC50 = 0.41 nM [530249]
FGGFTGARKSARKLKNQ Drug Info IC50 = 0.41 nM [529719]
FGGFTGARKSARKLYNQ Drug Info IC50 = 1 nM [529719]
FGGFTRKRKSARKLANQ Drug Info IC50 = 13 nM [529719]
FGGFTGARKSARKRKRK Drug Info IC50 = 0.42 nM [529719]
FGGFTGARKSARKRKNQ Drug Info IC50 = 0.21 nM [530249]
EtBut-RYYRIK-NH2 Drug Info IC50 = 92.6 nM [529208]
FGGFTGARKSARKKWNQ Drug Info IC50 = 0.31 nM [530249]
FGGFTGARKRKRKLANQ Drug Info IC50 = 0.94 nM [529719]
FGGFTGARKSARKLFNQ Drug Info IC50 = 1 nM [529719]
FGGFTGARKSARKKRNQ Drug Info IC50 = 0.21 nM [529719]
FGGFTGARKSARKYANQ Drug Info IC50 = 1.1 nM [529719]
FGGFTGARKSARKLVNQ Drug Info IC50 = 2.2 nM [529719]
FGGFTGARKSARKLRNQ Drug Info IC50 = 0.31 nM [529719]
NOCICEPTIN Drug Info IC50 = 0.73 nM [529719]
FGGFTGARKSARKRWNQ Drug Info IC50 = 0.3 nM [530249]
FGGFTGARKSARKAANQ Drug Info IC50 = 1.5 nM [529719]
FGGFTGARKSARKLARK Drug Info IC50 = 0.54 nM [529719]
IsoBu-RYYRIK-NH2 Drug Info IC50 = 2.81 nM [529208]
[D-Asp7,Lys10]N/OFQ(1-13)NH2 Drug Info Ki = 1.79 nM [529593]
[Asp6,Lys10]N/OFQ(1-13)NH2 Drug Info Ki = 0.54 nM [529593]
Cyclo[DAsp7,Lys10]N/OFQ(1-13)NH2 Drug Info Ki = 0.27 nM [529593]
1-benzhydryl-4-cyclopropylpiperidin-4-ol Drug Info Ki = 376 nM [528781]
4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol Drug Info Ki = 3 nM [528785]
F-G-G-F-T-G-A-R-K-S-Aib-R-K-L-A-N-Q-COOH Drug Info Ki = 0.48 nM [526456]
F-G-G-F-T-G-A-R-K-S-MeA-R-K-L-A-N-Q-COOH Drug Info Ki = 20 nM [526456]
F-G-G-F-T-G-MeA-R-K-S-A-R-K-L-A-N-Q-COOH Drug Info Ki = 15 nM [526456]
F-G-G-F-T-G-A-R-K-S-MeA-R-K-L-A-N-Q-CONH2 Drug Info Ki = 6.7 nM [526456]
F-G-G-F-T-G-A-R-K-S-A-R-K-L-Aib-N-Q-COOH Drug Info Ki = 0.15 nM [526456]
4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol Drug Info Ki = 53 nM [528785]
1-benzhydryl-4-(4-ethylphenyl)piperidin-4-ol Drug Info Ki = 1281 nM [528781]
4-phenyl-1-(1-phenylhexyl)piperidin-4-ol Drug Info Ki = 14 nM [528785]
4-(2-(aminomethyl)phenyl)-1-benzylpiperidin-4-ol Drug Info Ki = 455 nM [528781]
1-benzhydryl-4-butylpiperidin-4-ol Drug Info Ki = 23 nM [528781]
1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol Drug Info Ki = 16 nM [528785]
1-benzhydryl-4-benzylpiperidin-4-ol Drug Info Ki = 2176 nM [528781]
1-benzhydryl-4-(4-butylphenyl)piperidin-4-ol Drug Info Ki = 9155 nM [528781]
FGGFTGARKSARKWRNQ Drug Info IC50 = 0.23 nM [530249]
1-benzhydryl-4-p-tolylpiperidin-4-ol Drug Info Ki = 55 nM [528781]
Bz--RYYRIK-NH2 Drug Info IC50 = 14.7 nM [529208]
FGGFTGARKSARKLADE Drug Info IC50 = 0.286 nM [526185]
FGGFTGARKSARKKANQ Drug Info IC50 = 0.41 nM [529719]
1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol Drug Info Ki = 14 nM [528781]
1-benzhydryl-4-ethoxy-4-phenylpiperidine Drug Info Ki = 59 nM [528785]
1-benzhydryl-4-isopropylpiperidin-4-ol Drug Info Ki = 433 nM [528781]
1-benzhydryl-4-tert-butylpiperidin-4-ol Drug Info Ki = 62 nM [528781]
4-phenyl-1-(1-phenylheptyl)piperidin-4-ol Drug Info Ki = 18 nM [528785]
1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol Drug Info Ki = 51 nM [528781]
1-benzhydryl-4-(benzyloxy)-4-phenylpiperidine Drug Info Ki = 162 nM [528785]
1-benzhydryl-4-phenyl-4-propoxypiperidine Drug Info Ki = 72 nM [528785]
1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol Drug Info Ki = 48 nM [528781]
1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol Drug Info Ki = 85 nM [528781]
1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol Drug Info Ki = 24 nM [528781]
1-benzhydryl-4-m-tolylpiperidin-4-ol Drug Info Ki = 27 nM [528781]
1-benzhydryl-4-methoxy-4-phenylpiperidine Drug Info Ki = 54 nM [528785]
1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol Drug Info Ki = 34 nM [528781]
1-(3,3-diphenylpropyl)-4-phenylpiperidin-4-ol Drug Info Ki = 613 nM [528785]
Ac-Phe-[Orn-Pro-cha-Trp-Arg] Drug Info IC50 = 2200 nM [528343]
1-benzhydryl-4-phenylpiperidin-4-ol Drug Info Ki = 13 nM [530052]
1-benzhydryl-4-(pyridin-2-yl)piperidin-4-ol Drug Info Ki = 313 nM [528781]
FGGFTGARKSARKRRNQ Drug Info IC50 = 0.27 nM [529719]
Ac-RYYRIK-K-(NH2)-YAFGYPS Drug Info IC50 = 11.6 nM [528282]
1-benzhydryl-4-cyclohexylpiperidin-4-ol Drug Info Ki = 17 nM [528781]
FLUPERAMIDE Drug Info Ki = 2151 nM [527228]
Ac-RYYRIK-K-(NH2)-YRFB Drug Info IC50 = 0.789 nM [528282]
FGGFTGARKSARKWKNQ Drug Info IC50 = 0.25 nM [530249]
1-benzhydryl-4-(4-propylphenyl)piperidin-4-ol Drug Info Ki = 1745 nM [528781]
1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol Drug Info Ki = 588 nM [528781]
1-benzyl-4-phenylpiperidin-4-ol Drug Info Ki = 1983 nM [528785]
4-phenyl-1-(1-phenylpropyl)piperidin-4-ol Drug Info Ki = 135 nM [528785]
1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol Drug Info Ki = 134 nM [528785]
4-phenyl-1-(1-phenylbutyl)piperidin-4-ol Drug Info Ki = 19 nM [528785]
4-phenyl-1-(1-phenylpentyl)piperidin-4-ol Drug Info Ki = 5 nM [528785]
4-phenyl-1-(1-phenylethyl)piperidin-4-ol Drug Info Ki = 323 nM [528785]
1-benzhydryl-4-o-tolylpiperidin-4-ol Drug Info Ki = 11 nM [528781]
1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol Drug Info Ki = 180 nM [528781]
1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol Drug Info Ki = 23 nM [528781]
F-G-G-F-T-G-Aib-R-K-S-A-R-K-L-A-N-Q-COOH Drug Info Ki = 0.1 nM [526456]
Cyclo-[Asp6,Lys10]N/OFQ(1-13)NH2 Drug Info Ki = 0.34 nM [529593]
Cyclo[Cys7,Cys10]N/OFQ(1-13)NH2 Drug Info Ki = 0.1 nM [529593]
3-(1-benzylpiperidin-4-yl)-5-chloro-1H-indole Drug Info Ki = 1140 nM [528151]
F-G-G-F-T-G-MeA-R-K-S-A-R-K-L-A-N-Q-CONH2 Drug Info Ki = 2.2 nM [526456]
F-G-G-F-T-G-A-R-K-S-A-R-K-L-MeA-N-Q-COOH Drug Info Ki = 1.1 nM [526456]
Cyclo[Cys6,Cys10]N/OFQ(1-13)NH2 Drug Info Ki = 0.83 nM [529593]
FGGFTGARKSARKLWNQ Drug Info IC50 = 2.1 nM [530249]
FGGFTGARKSARKRANQ Drug Info IC50 = 0.33 nM [529719]
FGGFTGARKSARKFANQ Drug Info IC50 = 1.1 nM [529719]
H-RYYRIK-NH2 Drug Info IC50 = 218 nM [529208]
Pr-RYYRIK-NH2 Drug Info IC50 = 1.7 nM [529208]
References
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 529208Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. Epub 2007 Nov 21.Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist.
Ref 529208Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. Epub 2007 Nov 21.Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist.
Ref 529208Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. Epub 2007 Nov 21.Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist.
Ref 526185J Med Chem. 2001 Nov 8;44(23):4015-8.Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nociceptin peptides.
Ref 529208Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. Epub 2007 Nov 21.Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist.
Ref 526185J Med Chem. 2001 Nov 8;44(23):4015-8.Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nociceptin peptides.
Ref 529208Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. Epub 2007 Nov 21.Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist.
Ref 526185J Med Chem. 2001 Nov 8;44(23):4015-8.Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nociceptin peptides.
Ref 529208Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. Epub 2007 Nov 21.Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist.
Ref 529208Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. Epub 2007 Nov 21.Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist.
Ref 526185J Med Chem. 2001 Nov 8;44(23):4015-8.Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nociceptin peptides.
Ref 529208Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. Epub 2007 Nov 21.Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist.
Ref 529208Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. Epub 2007 Nov 21.Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist.
Ref 529208Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. Epub 2007 Nov 21.Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist.
Ref 529208Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. Epub 2007 Nov 21.Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist.
Ref 529719Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. Epub 2008 Sep 9.Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation.
Ref 529719Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. Epub 2008 Sep 9.Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation.
Ref 529719Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. Epub 2008 Sep 9.Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation.
Ref 526185J Med Chem. 2001 Nov 8;44(23):4015-8.Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nociceptin peptides.
Ref 530249Bioorg Med Chem. 2009 Aug 1;17(15):5683-7. Epub 2009 Jun 13.Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)(14), (Arg/Lys)(15)]nociceptin on ORL1 receptor binding and activation.
Ref 529719Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. Epub 2008 Sep 9.Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation.
Ref 529719Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. Epub 2008 Sep 9.Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation.
Ref 529719Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. Epub 2008 Sep 9.Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation.
Ref 529719Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. Epub 2008 Sep 9.Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation.
Ref 530249Bioorg Med Chem. 2009 Aug 1;17(15):5683-7. Epub 2009 Jun 13.Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)(14), (Arg/Lys)(15)]nociceptin on ORL1 receptor binding and activation.
Ref 529208Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. Epub 2007 Nov 21.Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist.
Ref 530249Bioorg Med Chem. 2009 Aug 1;17(15):5683-7. Epub 2009 Jun 13.Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)(14), (Arg/Lys)(15)]nociceptin on ORL1 receptor binding and activation.
Ref 529719Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. Epub 2008 Sep 9.Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation.
Ref 529719Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. Epub 2008 Sep 9.Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation.
Ref 529719Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. Epub 2008 Sep 9.Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation.
Ref 529719Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. Epub 2008 Sep 9.Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation.
Ref 529719Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. Epub 2008 Sep 9.Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation.
Ref 529719Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. Epub 2008 Sep 9.Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation.
Ref 529719Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. Epub 2008 Sep 9.Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation.
Ref 530249Bioorg Med Chem. 2009 Aug 1;17(15):5683-7. Epub 2009 Jun 13.Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)(14), (Arg/Lys)(15)]nociceptin on ORL1 receptor binding and activation.
Ref 529719Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. Epub 2008 Sep 9.Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation.
Ref 529719Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. Epub 2008 Sep 9.Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation.
Ref 529208Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. Epub 2007 Nov 21.Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist.
Ref 529593J Med Chem. 2008 Aug 14;51(15):4385-7. Epub 2008 Jul 15.High affinity conformationally constrained nociceptin/orphanin FQ(1-13) amide analogues.
Ref 529593J Med Chem. 2008 Aug 14;51(15):4385-7. Epub 2008 Jul 15.High affinity conformationally constrained nociceptin/orphanin FQ(1-13) amide analogues.
Ref 529593J Med Chem. 2008 Aug 14;51(15):4385-7. Epub 2008 Jul 15.High affinity conformationally constrained nociceptin/orphanin FQ(1-13) amide analogues.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 526456J Med Chem. 2002 Nov 21;45(24):5280-6.Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints.
Ref 526456J Med Chem. 2002 Nov 21;45(24):5280-6.Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints.
Ref 526456J Med Chem. 2002 Nov 21;45(24):5280-6.Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints.
Ref 526456J Med Chem. 2002 Nov 21;45(24):5280-6.Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints.
Ref 526456J Med Chem. 2002 Nov 21;45(24):5280-6.Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints.
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 530249Bioorg Med Chem. 2009 Aug 1;17(15):5683-7. Epub 2009 Jun 13.Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)(14), (Arg/Lys)(15)]nociceptin on ORL1 receptor binding and activation.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 529208Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. Epub 2007 Nov 21.Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist.
Ref 526185J Med Chem. 2001 Nov 8;44(23):4015-8.Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nociceptin peptides.
Ref 529719Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. Epub 2008 Sep 9.Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 528343Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92. Epub 2006 Jul 28.Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivoactivity.
Ref 530052Bioorg Med Chem Lett. 2009 May 1;19(9):2519-23. Epub 2009 Mar 14.The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 529719Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. Epub 2008 Sep 9.Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation.
Ref 528282Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41. Epub 2006 Jun 30.Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-amide.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 527228Bioorg Med Chem Lett. 2004 Nov 1;14(21):5275-9.Design and synthesis of 4-phenyl piperidine compounds targeting the mu receptor.
Ref 528282Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41. Epub 2006 Jun 30.Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-amide.
Ref 530249Bioorg Med Chem. 2009 Aug 1;17(15):5683-7. Epub 2009 Jun 13.Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)(14), (Arg/Lys)(15)]nociceptin on ORL1 receptor binding and activation.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 526456J Med Chem. 2002 Nov 21;45(24):5280-6.Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints.
Ref 529593J Med Chem. 2008 Aug 14;51(15):4385-7. Epub 2008 Jul 15.High affinity conformationally constrained nociceptin/orphanin FQ(1-13) amide analogues.
Ref 529593J Med Chem. 2008 Aug 14;51(15):4385-7. Epub 2008 Jul 15.High affinity conformationally constrained nociceptin/orphanin FQ(1-13) amide analogues.
Ref 528151Bioorg Med Chem Lett. 2006 Jul 1;16(13):3524-8. Epub 2006 Apr 24.3-(4-Piperidinyl)indoles and 3-(4-piperidinyl)pyrrolo-[2,3-b]pyridines as ligands for the ORL-1 receptor.
Ref 526456J Med Chem. 2002 Nov 21;45(24):5280-6.Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints.
Ref 526456J Med Chem. 2002 Nov 21;45(24):5280-6.Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints.
Ref 529593J Med Chem. 2008 Aug 14;51(15):4385-7. Epub 2008 Jul 15.High affinity conformationally constrained nociceptin/orphanin FQ(1-13) amide analogues.
Ref 530249Bioorg Med Chem. 2009 Aug 1;17(15):5683-7. Epub 2009 Jun 13.Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)(14), (Arg/Lys)(15)]nociceptin on ORL1 receptor binding and activation.
Ref 529719Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. Epub 2008 Sep 9.Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation.
Ref 529719Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. Epub 2008 Sep 9.Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation.
Ref 529208Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. Epub 2007 Nov 21.Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist.
Ref 529208Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. Epub 2007 Nov 21.Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.